Biogen (BIIB) Other Non-Current Liabilities (2009 - 2026)

Biogen (BIIB) has reported Other Non-Current Liabilities for 18 consecutive years, with $787.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 4.71% year-over-year to $787.1 million; the TTM figure through Mar 2026 stood at $787.1 million (up 4.71% YoY), while the FY2025 annual figure was $748.5 million, up 2.21% from the prior year.
• Other Non-Current Liabilities came in at $787.1 million for Q1 2026 at Biogen, up from $748.5 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $1.3 billion in Q1 2022, with the low at $556.7 million in Q2 2024.
• Average Other Non-Current Liabilities over 5 years is $852.8 million, with a median of $777.1 million recorded in 2024.
• Across the five-year window, Other Non-Current Liabilities sank 37.58% in 2023 and soared 43.63% in 2025, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $944.2 million in 2022, then slipped by 17.27% to $781.1 million in 2023, then declined by 6.25% to $732.3 million in 2024, then grew by 2.21% to $748.5 million in 2025, then grew by 5.16% to $787.1 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $787.1 million, $748.5 million, and $761.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.